Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06318897 2026-03-04

Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer

Phase 2 Recruiting

28 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06976944 2026-02-23

PRELUDE

Phase 2 Recruiting

44 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04683679 2026-02-17

A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

Phase 2 Recruiting

34 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07188246 2026-02-11

BRINK

Phase 2 Recruiting

40 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05082259 2026-02-10

ASTEROID

Phase 1 Recruiting

61 enrolled

BreastGynecologic

Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms

NCT02432963 2026-01-28

Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy

Phase 1 Active not recruiting

11 enrolled

BreastDermatologicGastrointestinalGenitourinaryHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Carcinoma, Hepatocellular, Melanoma, Pancreatic Neoplasms, Rectal Neoplasms, Sarcoma, Triple Negative Breast Neoplasms

NCT06324240 2026-01-26

Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer

Phase 1 Recruiting

18 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02411656 2026-01-23

Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy

Phase 2 Active not recruiting

71 enrolled 11 charts

Breast

Edema, Erythema, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04095689 2026-01-23

INTEGRAL

Phase 2 Terminated

8 enrolled 10 charts

Breast

Triple Negative Breast Neoplasms

NCT06353997 2026-01-15

Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients

Phase 2 Recruiting

12 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07341867 2026-01-14

Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

Phase 1 Not yet recruiting

90 enrolled

BreastPlasma cell

Multiple Myeloma, Triple Negative Breast Neoplasms

NCT03225547 2025-12-23

Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer

Phase 2 Terminated

24 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04427293 2025-12-16

Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)

Phase 1 Recruiting

12 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06081244 2025-11-19

ADAPT-TN-III

Phase 3 Recruiting

348 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05973864 2025-11-17

CAPPA

Phase 2 Recruiting

220 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06078384 2025-11-17

ETNA

Phase 2 Recruiting

354 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07016399 2025-10-30

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

Phase 2 Recruiting

51 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04443348 2025-10-14

Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)

Phase 2 Active not recruiting

120 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04954599 2025-10-07

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Phase 1/2 Recruiting

126 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT03362060 2025-10-01

PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer

Phase 1 Active not recruiting

20 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06245889 2025-09-23

NeoADAPT

Phase 2 Recruiting

30 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04335669 2025-09-12

NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

Phase 3 Active not recruiting

325 enrolled

Breast

Pathologic Complete Response, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06606730 2025-08-26

OPT-PEMBRO

Phase 3 Recruiting

2,454 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05491083 2025-07-25

ComPACT

Phase 1/2 Recruiting

51 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05714553 2025-07-18

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

Phase 1/2 Terminated

19 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Esophageal Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms